申请人:Gibbons Paul
公开号:US08999998B2
公开(公告)日:2015-04-07
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
公式I的化合物,对映异构体,顺反异构体,互变异构体或其药学上可接受的盐,其中R1、R2和R3在此定义中,可用作一种或多种JAK抑制剂。本发明还公开了一种包括公式I化合物和药学上可接受的载体、佐剂或载体的制药组合物,以及治疗或减轻患者对JAK活性抑制反应的疾病或病情的方法。